1. Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302–308 (2014). Doi: 10.1038/nature12981
2. Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Duso, B., & Curigliano, G. (2019). Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Translational Research And Onco-Omics Applications In The Era Of Cancer Personal Genomics, 9-30. doi: 10.1007/978-3-030-24100-1_2
3. Mandelker, D., Donoghue, M., Talukdar, S., Bandlamudi, C., Srinivasan, P., & Vivek, M. et al. (2019). Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Annals Of Oncology, 30(8), 1221-1231. doi: 10.1093/annonc/mdz136
4. Li, M., Chao, E., Esplin, E., Miller, D., Nathanson, K., & Plon, S. et al. (2020). Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics In Medicine, 22(7), 1142-1148. doi: 10.1038/s41436-020-0783-8
5. Forbes, C., Fayter, D., de Kock, S., & Quek, R. (2019). A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA mutated breast cancer. Cancer Management And Research, Volume 11, 2321-2337. doi: 10.2147/cmar.s189627
6. Khiabanian, H., Hirshfield, K., Goldfinger, M., Bird, S., Stein, M., & Aisner, J. et al. (2018). Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. JCO Precision Oncology, (2), 1-15. doi: 10.1200/po.17.00148.
7. Hiltemann, S., Jenster, G., Trapman, J., van der Spek, P., & Stubbs, A. (2015). Discriminating somatic and germline mutations in tumor DNA samples without matching normals. Genome Research, 25(9), 1382-1390. doi: 10.1101/gr.183053.114
8. Park, S., Supek, F., & Lehner, B. (2018). Systematic discovery of germline cancer predisposition genes through the identification of somatic second hits. Nature Communications, 9(1). doi: 10.1038/s41467-018-04900-7
9. Sun, J., He, Y., Sanford, E., Montesion, M., Frampton, G., & Vignot, S. et al. (2018). A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLOS Computational Biology, 14(2), e1005965. doi: 10.1371/journal.pcbi.1005965
10. Report Linker. Real-World Evidence Solutions Market - Growth, Trends, and Forecasts (2020 - 2025). Retrieved 09 April 2021, from https://www.reportlinker.com/p05974125/Real-World-Evidence-Solutions-Market-Growth-Trends-and-Forecasts.html
11. Research and Market. North America Digital Genome Market 2021-2028. Retrieved 09 April 2021, from https://www.researchandmarkets.com/reports/5264345/north-america-digital-genome-market-2021-2028
12. International Conference of Harmonization. Guideline for Good Clinical Practices (2016) -. Retrieved 09 April 2021, from https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf.
13. Knudson, A. (1971). Mutation and Cancer: Statistical Study of Retinoblastoma. Proceedings Of The National Academy Of Sciences, 68(4), 820-823. doi: 10.1073/pnas.68.4.820
14. James, G., Witten, D., Hastie, T., & Tibshirani, R. (2013). An introduction to statistical learning (1st ed.). New-York, NY: Springer. doi: 10.1007/978-1-4614-7138-7
15. Castellanos, E., Gel, B., Rosas, I., Tornero, E., Santín, S., & Pluvinet, R. et al. (2017). A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. Scientific Reports, 7(1). doi: 10.1038/srep39348
16. Mandelker, D., Zhang, L., Kemel, Y., Stadler, Z., Joseph, V., & Zehir, A. et al. (2017). Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA, 318(9), 825. doi: 10.1001/jama.2017.11137
17. Meric-Bernstam, F., Brusco, L., Daniels, M., Wathoo, C., Bailey, A., & Strong, L. et al. (2016). Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals Of Oncology, 27(5), 795-800. doi: 10.1093/annonc/mdw018
18. Winter, C., Nilsson, M., Olsson, E., George, A., Chen, Y., & Kvist, A. et al. (2016). Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Annals Of Oncology, 27(8), 1532-1538. doi: 10.1093/annonc/mdw209
19. Corso, G., Intra, M., Trentin, C., Veronesi, P., & Galimberti, V. (2016). CDH1 germline mutations and hereditary lobular breast cancer. Familial Cancer, 15(2), 215-219. doi: 10.1007/s10689-016-9869-5
20. Oak, N., Cherniack, A.D., Mashl, R.J. et al. (2020). Ancestry-specific predisposing germline variants in cancer. Genome Med 12, 51. doi: 10.1186/s13073-020-00744-3
21. Ménard, T., Barros, A., & Ganter, C. (2021). Clinical quality considerations when using Next-Generation Sequencing (NGS) in clinical drug development. Ther Innov Regul Sci. doi: 10.1007/s43441-021-00308-6
22. Aloraifi, F., Alshehhi, M., McDevitt, T., Cody, N., Meany, M., & O'Doherty, A. et al. (2015). Phenotypic analysis of familial breast cancer: Comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer. European Journal Of Surgical Oncology (EJSO), 41(5), 641-646. doi: 10.1016/j.ejso.2015.01.021
23. Gliklich, R., & Leavy, M. (2020). Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence. Therapeutic Innovation & Regulatory Science, 54(2), 303-307. doi: 10.1007/s43441-019-00058-6
24. Leon, P., Cancel‐Tassin, G., Bourdon, V., Buecher, B., Oudard, S., & Brureau, L. et al. (2021). Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer. The Prostate. doi: 10.1002/pros.24109
25. Ménard, T., Barmaz, Y., Koneswarakantha, B., Bowling, R., & Popko, L. (2019). Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning. Drug Safety, 42(9), 1045-1053. doi: 10.1007/s40264-019-00831-4
26. Ménard, T., Bowling, R., Mehta, P., Koneswarakantha, B., & Magruder, E. (2020). Leveraging analytics to assure quality during the Covid-19 pandemic - The COVACTA clinical study example. Contemporary Clinical Trials Communications, 20, 100662. doi: 10.1016/j.conctc.2020.100662
27. Ménard, T. (2021). Letter to the Editor: New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19. Therapeutic Innovation & Regulatory Science. doi: 10.1007/s43441-021-00281-0
28. Ménard, T., Young, K., Siegel, L., Emerson, J., Studt, R. & Sidor, L. (2021). The IMPALA Industry Group. Cross- company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group. CPT Pharmacometrics Syst Pharmacol. doi: 10.1002/psp4.12677